Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.

CONCLUSIONS: Twice daily schedule of re-irradiation of 60 Gy/5 weeks with cetuximab was tolerable and no significant difference in treatment delays occurred between two arms. PMID: 29784451 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29784451?dopt=Abstract

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - May 18, 2018 Category: Radiology Authors: Tao Y, Faivre L, Laprie A, Boisselier P, Ferron C, Jung GM, Racadot S, Gery B, Even C, Breuskin I, Bourhis J, Janot F Tags: Radiother Oncol Source Type: research